-
New drug outbreak!
Time of Update: 2022-04-29
On the same day, Sihuan Pharmaceutical announced that XZP-KM257, the first class 1 macromolecule innovative drug independently developed by Xuanzhu Bio, a subsidiary of the Group, has been approved for clinical trials, and is indicated for the treatment of advanced solid tumors with medium and high expression of HER2+.
-
Nearly 200 kinds of Chinese herbal medicines may be collected on a large scale across provinces!
Time of Update: 2022-04-29
At present, the Ningxia Medical Insurance Bureau has issued the "Notice of the Autonomous Region Medical Insurance Bureau on Carrying out the Data Reporting Work of Some TCM Decoction Pieces", which clarifies that the National Inter-Provincial Traditional Chinese Medicine (Material) Procurement Alliance has begun to report the amount of TCM decoction pieces .
-
65 pharmaceutical companies have received institutional attention, and many have received more than 200 institutional investigators
Time of Update: 2022-04-29
A number of companies have obtained more than 200 institutional investigators, including Mindray Medical, Junshi Bio, and Huadong Medicine .
-
Special reminder from the National Medical Insurance Administration: Do not click on the link when you receive this kind of information
Time of Update: 2022-04-29
At present, in response to such telecommunication fraud, we remind you again that the insured must pay attention to the fact that the domain names of the National Medical Security Administration website all end with nhsa.
-
Within 3 months, there have been changes in the executives of 90 pharmaceutical companies!
Time of Update: 2022-04-29
On March 3, BeiGene issued an announcement stating that Jane Huang (Huang Weijuan), a company executive and core technician, is considering applying for resignation in the near future due to personal career planning, and will officially resign as the company’s chief hematology on April 3, 2022 local time in the United States Medical officer post .
-
Overweight innovative drug research and development, domestic pharmaceutical companies are providing more new drug options
Time of Update: 2022-04-29
98 billion yuan and issue no more than 70 million shares, which will be used for innovative drug research and development projects and Shanghai Junshi.
In addition to Junshi Bio, many pharmaceutical companies are currently increasing investment in the research and development of innovative drugs .
-
The pharmaceutical outsourcing sector went up on March 10. What will happen next?
Time of Update: 2022-04-29
The industry believes that the Wuxi base has passed the PAI of the first EMA formulation project, which means that WuXi AppTec's layout in the global CXO market has reached a new level .
-
Pharmaceutical companies in centralized procurement are also facing this major challenge!
Time of Update: 2022-04-29
The announcement pointed out that the pharmaceutical company was selected as the third batch of Ibuprofen Sustained-Release Capsules for the centralized procurement of drugs organized by the state, but it failed to supply the agreed procurement volume in Shandong Province according to the agreement.
-
Multinational pharmaceutical companies have achieved good results in the Chinese market, and one company has soared by 60%
Time of Update: 2022-04-29
Eight multinational pharmaceutical companies including Roche, AstraZeneca, Bayer, Merck, Sanofi, Novartis, Novo Nordisk and Eli Lilly have achieved good growth in the Chinese market as a whole .
-
Another batch of drugs passed the consistency evaluation, and more than 200 varieties have been evaluated in 2022!
Time of Update: 2022-04-29
As of the disclosure date of this announcement, one domestic company, Yangtze River Pharmaceuticals, has passed the consistency evaluation of this variety .
Fangsheng Pharmaceutical also issued an announcement on the evening of March 8 that cefixime tablets passed the quality and efficacy consistency evaluation of generic drugs .
-
New research on traceability further supports the origin of the new coronavirus in nature
Time of Update: 2022-04-29
Two reports by researchers from the University of Arizona and other institutions combed data and information from multiple sources such as the World Health Organization, and analyzed the characteristics of virus transmission in the early stages of the epidemic .
-
In order to enhance market competitiveness, domestic pharmaceutical companies have set off a wave of acquisitions
Time of Update: 2022-04-29
Recently, Proton shares announced that in order to meet the rapid growth of preclinical and early clinical (CRO) business development needs, the company plans to acquire 100% equity of Kaihui Pharmaceutical held by Ruizhi Chemical at a price of RMB 266 million in cash.
-
From January to February 2022, CDE will undertake a total of 220 new Chinese medicine registration applications, including 13 new medicines
Time of Update: 2022-04-29
With the support of frequent policies, domestic innovative Chinese medicine drugs have reached new highs in both the number of applications and the number of approvals .
-
Representatives call for the introduction of a nurse law to address the shortage of nursing staff
Time of Update: 2022-04-29
This year, the representatives and committee members offered suggestions on strengthening the construction of primary medical institutions, helping the elderly to seek medical treatment through technology, and improving the nursing practice system .
-
A batch of drugs did not meet the regulations and was fined 330,000 yuan!
Time of Update: 2022-04-28
The company's batch of drugs failed to meet the regulations after inspection, and a total of 330,000 yuan was fined .
For example, the new version of the Pharmacopoeia has put forward strict management requirements for the production of the Chinese medicine decoction piece industry .
-
Failure to improve progression-free survival!
Time of Update: 2022-04-28
On March 14, Sanofi announced the results of the clinical trial (AMEERA-3) of amcenestrant as a monotherapy for second- or multi-line treatment of ER+/HER2- advanced or metastatic breast cancer .
-
In 2022, the market size of Chinese medicine decoction pieces will exceed 260 billion, and opportunities and challenges coexist in the decoction piece machinery industry
Time of Update: 2022-04-28
Opportunities and challenges coexist in the decoction piece machinery industry (Source: Pharmaceutical Network) Combining market, policy and other factors, the industry generally expresses its optimism about the prospects of the Chinese medicine decoction pieces market.
-
Since 2022, more than 6 multinational pharmaceutical company executives have left
Time of Update: 2022-04-28
On February 24, Abbott's internal news said that the organizational structure of the core diagnostics business unit was adjusted, and Tony Chan, Abbott's global vice president and president of China's core diagnostics, decided to seek external opportunities .
-
The traditional Chinese medicine industry has ushered in a period of opportunity, and a large number of enterprises will benefit
Time of Update: 2022-04-28
The industry expects that in the next few years, benefiting from the successive implementation of favorable policies in the Chinese medicine sector, the Chinese medicine industry will usher in a period of development opportunities .
-
China's National Medical Products Administration Approves Baizean(R) for the treatment of patients with microsatellite highly unstable or mismatch repair gene-deficient solid tumors
Time of Update: 2022-04-28
BEIJING, China and CAMBRIDGE, Mass. , March 11, 2022 /PRNewswire/ -- BeiGene announced today that China's National Medical Products Administration (NMPA) has granted conditional approval to its anti-P
